Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Bentham

Showing results (41-50 of 55) with videos related to

Pageof 6
Sort By:
Health Technology Assessment (Winchester, England)|November 6, 2023
A pragmatic, multicentre, double-blind, placebo-controlled randomised trial to assess the safety, clinical and cost-effectiveness of mirtazapine and carbamazepine in people with Alzheimer's disease and agitated behaviours: the HTA-SYMBAD trialSube Banerjee, Nicolas Farina, Catherine Henderson, et al.
Lancet (London, England)|November 20, 2016
Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trialSerge Gauthier, Howard H Feldman, Lon S Schneider, et al.
Health Technology Assessment (Winchester, England)|December 4, 2018
Amisulpride for very late-onset schizophrenia-like psychosis: the ATLAS three-arm RCTRobert Howard, Elizabeth Cort, Rosie Bradley, et al.
International Journal of Geriatric Psychiatry|October 15, 2016
Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO-AD trial)Martin Knapp, Derek King, Renée Romeo, et al.
The Lancet. Neurology|October 31, 2015
Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analysesRobert Howard, Rupert McShane, James Lindesay, et al.
Journal of Alzheimer'S Disease : JAD|November 21, 2017
Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical TrialGordon K Wilcock, Serge Gauthier, Giovanni B Frisoni, et al.
International Journal of Geriatric Psychiatry|September 18, 2010
Determining the minimum clinically important differences for outcomes in the DOMINO trialRobert Howard, Patrick Phillips, Tony Johnson, et al.
Journal of Alzheimer'S Disease : JAD|April 14, 2020
Concentration-Dependent Activity of Hydromethylthionine on Clinical Decline and Brain Atrophy in a Randomized Controlled Trial in Behavioral Variant Frontotemporal DementiaHelen Shiells, Bjoern O Schelter, Peter Bentham, et al.
Age and Ageing|January 25, 2021
The effectiveness and cost-effectiveness of assistive technology and telecare for independent living in dementia: a randomised controlled trialRobert Howard, Rebecca Gathercole, Rosie Bradley, et al.
Trials|July 28, 2009
DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCTRob Jones, Bart Sheehan, Patrick Phillips, et al.
Pageof 6

Showing results (41-50 of 55) with videos related to

Sort By:
Pageof 6
Health Technology Assessment (Winchester, England)|November 6, 2023
A pragmatic, multicentre, double-blind, placebo-controlled randomised trial to assess the safety, clinical and cost-effectiveness of mirtazapine and carbamazepine in people with Alzheimer's disease and agitated behaviours: the HTA-SYMBAD trialSube Banerjee, Nicolas Farina, Catherine Henderson, et al.
Lancet (London, England)|November 20, 2016
Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trialSerge Gauthier, Howard H Feldman, Lon S Schneider, et al.
Health Technology Assessment (Winchester, England)|December 4, 2018
Amisulpride for very late-onset schizophrenia-like psychosis: the ATLAS three-arm RCTRobert Howard, Elizabeth Cort, Rosie Bradley, et al.
International Journal of Geriatric Psychiatry|October 15, 2016
Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO-AD trial)Martin Knapp, Derek King, Renée Romeo, et al.
The Lancet. Neurology|October 31, 2015
Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analysesRobert Howard, Rupert McShane, James Lindesay, et al.
Journal of Alzheimer'S Disease : JAD|November 21, 2017
Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical TrialGordon K Wilcock, Serge Gauthier, Giovanni B Frisoni, et al.
International Journal of Geriatric Psychiatry|September 18, 2010
Determining the minimum clinically important differences for outcomes in the DOMINO trialRobert Howard, Patrick Phillips, Tony Johnson, et al.
Journal of Alzheimer'S Disease : JAD|April 14, 2020
Concentration-Dependent Activity of Hydromethylthionine on Clinical Decline and Brain Atrophy in a Randomized Controlled Trial in Behavioral Variant Frontotemporal DementiaHelen Shiells, Bjoern O Schelter, Peter Bentham, et al.
Age and Ageing|January 25, 2021
The effectiveness and cost-effectiveness of assistive technology and telecare for independent living in dementia: a randomised controlled trialRobert Howard, Rebecca Gathercole, Rosie Bradley, et al.
Trials|July 28, 2009
DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCTRob Jones, Bart Sheehan, Patrick Phillips, et al.
Pageof 6